Enlivex Receives FDA Clearance for Phase 2b Trial of Allocetra in Knee Osteoarthritis Treatment

Enlivex, a quality longevity company, has received FDA clearance for a Phase 2b trial of Allocetra in age-related primary moderate-to-severe knee osteoarthritis. The trial follows positive data from a Phase 1/2a trial that demonstrated a robust, durable, and clinically meaningful treatment effect in older patients. Enlivex's dual-engine value creation model is centered on developing a clinical-stage quality longevity program powered by a prediction markets treasury strategy.